Health Care • Industrial Specialties
$1.30 ▲ +0.04
(+3.18%)
MKT CAP: $51.5M • VOL: 249.5K
52W L $1 52W H $2
MYO // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $40.9M | $32.6M | $19.2M |
| YoY Revenue Growth % | +25.7% | +69.2% | — |
| Gross Profit | $26.9M | $23.2M | — |
| Gross Margin % | 65.7% | 71.2% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$14.4M | -$6.2M | -$8.2M |
| Operating Margin % | -35.2% | -19.1% | -42.8% |
| Net Income (GAAP) | -$15.6M | -$6.2M | -$8.1M |
| EBITDA (Normalized) | -$13.0M | -$5.1M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$14.5M | -$3.3M | -$6.2M |
| Capital Expenditures (CapEx) | $1.7M | $1.4M | — |
| Free Cash Flow (FCF) | -$16.3M | -$4.7M | -$6.2M |
| FCF Margin % | -39.7% | -14.3% | -32.1% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $14.1M | $24.4M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $11.4M | $24.7M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR MYO.